Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-07-16
1995-07-04
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514524, 514655, 546329, 564373, 564374, A61K 31135, A61K 3144, A61K 31275
Patent
active
054300444
ABSTRACT:
There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano;
R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl;
R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ;
R.sub.3 represents hydrogen or C1 to 6 alkyl;
REFERENCES:
patent: 2503285 (1950-04-01), McPhee
patent: 2604473 (1952-07-01), Sperber et al.
patent: 3420841 (1969-01-01), Brust et al.
patent: 3471612 (1969-10-01), Goonewardene
patent: 3510560 (1970-05-01), Saunders et al.
patent: 3692784 (1972-09-01), Lindberg
patent: 3992389 (1976-11-01), Cavalla et al.
patent: 4098764 (1978-07-01), Gencanelli et al.
patent: 4309424 (1982-01-01), Martin et al.
patent: 4769466 (1988-09-01), Griffith et al.
patent: 4822914 (1989-04-01), Martin et al.
patent: 4968721 (1990-11-01), Martin et al.
patent: 5047541 (1991-09-01), Griffith
patent: 5292760 (1994-03-01), Martin et al.
E. C. Dodds, W. Lawson, P. C. Williams--Royal Society Journal, 1943.
Medical Subject Headings, Tree Structures, 1992 pp. 165-174.
CA 102(19): 166-589y (1984), Shimada et al.
CA 86(15): 106314w (1976), Niemers et al.
CA 64,14162F, abstracting Zaheer et al., Ann. Chem. 691, 55-60 (1966).
CA 73,25044n, abstracting Novelli et al., Bol. Soc. Quim Peru, 35(3), 77-84 (1969).
CA 77,19586g, abstracting Patel et al., J. Indian Chem Soc. 49(2), 177-80 (1972).
CA 85,5705Y, Abstracting Japan Kokai 50/130776 (1975).
CA 96,19744Z, abstracting Antoniadau-Vyza et al., Prakt. Akad. Athenon, 54(A-B), 83-97 (1980).
J. C. Hubsch et al., "Determination of 2-Amino-N(1-Methyl-1-2-Diphenylethyl)Acetamide Monohydrochloride From A Ground Beef Matrix High Performance Liquid Chromatography", Abst. 127, Northeast Regional Meeting of the Am. Chem. Soc., Rochester, N.Y. Nov. 19, 1987.
G. C. Palmer et al., "A New Anticonvulsant, PR 934-423 Active Against Maximally Electroshock Seizures, III:Electrophysiological Studies".Abst. 317.17, Society of Neuroscience Meetings, New Orleans, La. (Nov. 16, 1987).
C. F. Luke et al., "Toxicity of a Novel Anticonvulsant, 2-Amino-N-(2-Methyl-1,2-Diphenylethyl)Acetamide, PR 934,423A"Abst. Society of Toxicology Annual Meeting, Dallas, Tex. (Feb. 15, 1988).
Griffith et al., "Synthesis and Anticonvulsant Activity of a Series of s-Amino-N-(1,2-Diphenylethyl)acetamides".Abst. 196th Natl. Meeting of the Am. Chem. Society, Los Angeles Calif. (Sep. 25-29, 1988).
Garske et al., "Preclinical Profile of Isomers of the Anticonvulsant PR 934-423". Society of Neuroscience Meeting, Toronto, Ont., Can. (Nov. 1988).
Stagnitto et al., "PR 1013-708, A Potent Anticonvulsant Against Maximal Electroshock Seizures (MES) in Rodents" Abst. Society of Neuroscience Meeting, Toronto, Ont. Can. (Nov. 1988).
Wilson et al., "Anticonvulsant Concentrations in CSF and Serum or Rats Protected Against MES by PR 934-423A". Abst. Society of Neuroscience Meeting, Toronto, Ont., Can (Nov. 1988).
Palmer et al., "Status of PR-934-423 A Novel Anticonvulsant Targeted For Generalized Toxic/Clinic Seizures (New Designation is FPL 12924AA)" Abst., Princeton Symposium, N.J. (May 1989).
Gosh et al., Arzneim-Forch./Drug Res. 28 (11) Heft 9 (1978) pp. 1561-1564 disclose a series of 1,2-diphenylethylamines as potential non-stimulant anoretics.
CA 84(9):59216n, abstracting German Offen. DE 241563 (1976) describes the preparation of pyridinylalkyalamidines from pyridylalkylamines.
CA 104(17):148472s, abstracting U.S. Patent 4,526,599, discloses diphenylalkylamines which are useful as pharmaceutical intermediates and optical resolution agents (1986).
Coughenour et al., Pharm. Biochem. Behav. 6,351 (1977).
Porter, Clev. Clin. Quarterly 51,293 (1984).
Shimada et al., Chem. Pharm. Bull. 32(12) 4893-906 (1984).
Niemers et al., Synthesis (9), 593-5 (1976).
Griffith Ronald C.
Napier James J.
Fisons Corporation
Lambkin Deborah
Raymond Richard L.
LandOfFree
Arylalkyl-amines and -amides having anticonvulsant and neuroprot does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylalkyl-amines and -amides having anticonvulsant and neuroprot, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylalkyl-amines and -amides having anticonvulsant and neuroprot will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-760357